InvestSMART

Living Cell Technologies Limited (ASX: LCT) - Announcements

- Current share price for LCT : $0.014

ASX company news and announcements for Living Cell Technologies Limited (LCT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Living Cell Technologies Limited (LCT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Living Cell Technologies Limited (LCT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Living Cell Technologies Limited (LCT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Appendix 4C - quarterly 27 Jul 2015 2:21PM $0.047 $0.014 fallen by 70.21%
$23 Proposed grant of options to Directors 14 Jul 2015 2:07PM $0.043 $0.014 fallen by 67.44%
$23 Update to DIABECELL development strategy 26 Jun 2015 2:46PM $0.050 $0.014 fallen by 72%
$23 LCT hosts conference call on Clinical Study in Parkinson's 18 Jun 2015 9:22AM $0.052 $0.014 fallen by 73.08%
$23 Parkinson's Congress NTCELL Poster Presentation 16 Jun 2015 9:10AM $0.074 $0.014 fallen by 81.08%
$23 NTCELL Clinical Study - Investor Conf. Call Time Correction 15 Jun 2015 1:23PM $0.074 $0.014 fallen by 81.08%
$23 NTCELL Clinical Study in Parkinson's Meets Endpoints 15 Jun 2015 8:54AM $0.066 $0.014 fallen by 78.79%
$23 Trading Halt 12 Jun 2015 4:28PM $0.066 $0.014 fallen by 78.79%
$23 CEO Remuneration 5 Jun 2015 3:31PM $0.060 $0.014 fallen by 76.67%
$23 Commentary on Appendix 4C 23 Apr 2015 3:45PM $0.056 $0.014 fallen by 75%
$23 Appendix 4C - quarterly 23 Apr 2015 3:40PM $0.056 $0.014 fallen by 75%
$23 LCT JV adopts new strategy for DIABECELL 5 Mar 2015 3:45PM n/a $0.014 n/a
$23 Half Yearly Report and Accounts 18 Feb 2015 12:49PM n/a $0.014 n/a
$23 Appendix 4C - quarterly 28 Jan 2015 1:35PM $0.061 $0.014 fallen by 77.05%
$23 LCT completes patient implants in Parkinson's trial 15 Dec 2014 10:05AM $0.065 $0.014 fallen by 78.46%
$23 Appendix 4C 30 Sep 2014 28 Oct 2014 2:38PM $0.065 $0.014 fallen by 78.46%
$23 LCT JV secures funds to realise the potential of DIABECELL 10 Oct 2014 2:25PM $0.064 $0.014 fallen by 78.13%
$23 Completion of $3m placement and SPP announced 8 Oct 2014 8:35AM $0.070 $0.014 fallen by 80%
$23 Successful second implant of NTCELL for Parkinson's 18 Aug 2014 11:50AM $0.059 $0.014 fallen by 76.27%
$23 Appendix 4E and Financial Statements 15 Aug 2014 2:51PM $0.054 $0.014 fallen by 74.07%
$23 Appendix 4C - quarterly 30 Jul 2014 1:03PM $0.053 $0.014 fallen by 73.58%
$23 Dr Ken Taylor appointed Chief Executive 8 Jul 2014 10:43AM $0.065 $0.014 fallen by 78.46%
$23 LCT Parkinson's trial resumes patient recruitment 23 Jun 2014 9:59AM $0.053 $0.014 fallen by 73.58%
$23 LCT to develop NTCELL independently 15 May 2014 10:43AM $0.056 $0.014 fallen by 75%
$23 Appendix 4C - quarterly 29 Apr 2014 12:00PM $0.060 $0.014 fallen by 76.67%

376 - 400 of 584 results

Page 16 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.